期刊
ACTA PAEDIATRICA
卷 107, 期 12, 页码 2172-2178出版社
WILEY
DOI: 10.1111/apa.14590
关键词
Behaviour; Child; Cognitive abilities; Probiotics
类别
资金
- Health Research Council of New Zealand
- Fonterra Co-operative Group Ltd, New Zealand
- Cure Kids New Zealand
Aim To determine whether probiotic supplementation in early life improves neurocognitive outcomes assessed at 11 years of age. Methods Results A total of 474 children who were born March 2004-Aug 2005 participated in a two-centre randomised placebo-controlled trial of infants at risk of developing allergic disease. Pregnant women were randomised to take Lactobacillus rhamnosus strain HN001, Bifidobacterium animalis subsp. lactis strain HN019 or placebo daily from 35 weeks gestation until six months if breastfeeding, and their infants the same treatment from birth to two years. Intelligence, executive function, attention, depression and anxiety were assessed when the children were 11 years of age. A total of 342 (72.2%) children were assessed (HN001 n = 109, HN019 n = 118 and placebo n = 115). Overall, there were no significant differences in the neurocognitive outcomes between the treatment groups. Conclusion HN001 and HN019 given in early life were not associated with neurocognitive outcomes at 11 years of age in this study. However, we cannot exclude that other probiotics may have a beneficial effect. Further clinical trials are indicated.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据